We are open to exploring partnerships that accelerate the development and reach of our RNA therapeutics platform.

ValamAi's mRNA platform is amenable to a broad range of nucleotide therapy approaches. We welcome conversations with pharmaceutical and biotechnology companies interested in co-development, licensing, or platform collaborations across our therapeutic areas of interest, including urology, orthopedic/spine indications, dermatology and oncology.

If you would like to discuss a potential partnership, please get in touch via our contact page and a member of our business development team will follow up.

Contact our business development team ›